Skip to main content
Premium Trial:

Request an Annual Quote

Cellular Dynamics Nets $43M in IPO

NEW YORK (GenomeWeb News) – Cellular Dynamics International said on Tuesday that it has closed its initial public offering, raising net proceeds of about $43 million.

The Madison, Wis.-based stem cell technologies firm, which went public last week, said it completed its offering of more than 3.8 million shares of common stock at $12.00 per share. The company trades on the Nasdaq under ticker symbol "ICEL".

CDI has offered its underwriters on the offering a 30-day option to purchase up to an additional 576,900 shares of its stock. JP Morgan Securities was the sole book-running agent, while Cowen & Co. and Leerink Swann were co-managers on the offering.

Proceeds from the offering will go toward research and product development work; sales and marketing activities, including expanding the firm's sales force, property, plant, and equipment; working capital; and other general corporate purposes.

CDI filed to go public in June.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.